No association between bone mass and prolactin levels among patients with schizophrenia

Sugawara, Norio; Yasui‐Furukori, Norio; Fujii, Akira; Saito, Manabu; Sato, Yasushi; Nakagami, Taku; Tsuchimine, Shoko; Kaneko, Sunao

doi:10.1002/hup.1250

Cited by 22 publications

(17 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have no significant difference in the results of PRL, which is consistent with the results of some studies [30][31][32]. However; some of studies had shown the opposite conclusion.…”

Section: Discussionsupporting

confidence: 91%

Prevalence and Factors Associated With Decreased Bone Mineral Density in Young and Middle-Aged Male Schizophrenic Patients

Shen¹,

Li²,

Huang³

et al. 2017

J Osteopor Phys Act

View full text Add to dashboard Cite

Objective: The prevalence and factors of decreased bone mineral density (BMD) in young and middle-aged schizophrenic male subjects were examined in this study. Methods:The sample included male patients, diagnosed with schizophrenia, between 18 and 45 years old. In the large-sample, cross-sectional study, cluster sampling method was adopted. 200 male inpatients in total, between 18 and 45 years old, diagnosed with schizophrenia, were included and interviewed in Beijing. The clinical assessment instruments included the Positive and Negative Syndrome Scale (PANSS) and a questionnaire with disease-related investigations and general information. The laboratory measurements concluded calcium, phosphorus, total cholesterol, prolactin (PRL), thyroid stimulating hormone, fT3, T3, fT4, T4, testosterone and fasting blood-glucose (FBG). Dual-energy X-ray absorptiometry was used to test BMD. Results:The prevalence of osteopenia or osteoporosis was 33.5% (n=67). The prevalence of fracture in decreased BMD group was 17.9%12/67, significantly higher than that in the normal BMD group 8.3%11/133(p<0.05). Decreased BMD was associated with PANSS-negative scores, PANSS-total scores, body mass index (BMI), smoking and weight. Multiple logistic regression analysis revealed that BMI and PANSS-negative score had statistically significant difference between two groups. Conclusion:Prevalence of decreased bone mineral density was higher in young and middle-aged male subjects with schizophrenia in China. And the prevalence of fracture was more than twice in the decreased BMD group compared with the normal BMD group. PANSS-negative symptom was a risk factor, while BMI was a protective factor.

show abstract

“…We have no significant difference in the results of PRL, which is consistent with the results of some studies [30][31][32]. However; some of studies had shown the opposite conclusion.…”

Section: Discussionsupporting

confidence: 91%

Prevalence and Factors Associated With Decreased Bone Mineral Density in Young and Middle-Aged Male Schizophrenic Patients

Shen¹,

Li²,

Huang³

et al. 2017

J Osteopor Phys Act

View full text Add to dashboard Cite

show abstract

“…It is likely that this reflects an antagonistic action of ( À )-OSU6162 on pituitary dopamine D2 receptors, which in the intact system mediate tonic inhibition of prolactin release. The highest prolactin levels observed in this study, however, were still 2-4 times lower than those found in male patients treated with therapeutic doses of amisulpiride (Bressan et al, 2004), and they were lower than mean prolactin levels in male patients with schizophrenia under antipsychotic treatment (Sugawara et al, 2011).…”

Section: Discussioncontrasting

confidence: 82%

The Dopamine Stabilizer (−)-OSU6162 Occupies a Subpopulation of Striatal Dopamine D2/D3 Receptors: An [11C]Raclopride PET Study in Healthy Human Subjects

Tolboom

Berendse

Leysen

et al. 2014

Neuropsychopharmacol

View full text Add to dashboard Cite

(-)-OSU6162 is a dopamine stabilizer that can counteract both hyperdopaminergic and hypodopaminergic states. In this study, D2/D3 receptor occupancy of (-)-OSU6162 in the human brain was investigated using positron emission tomography (PET). Twelve male healthy volunteers underwent [(11)C]raclopride PET scanning before and 1 h after a single oral dose of (-)-OSU6162 (15-90 mg). Blood samples for determination of (-)-OSU6162 and prolactin plasma levels were collected at Tmax. Parametric images of [(11)C]raclopride binding potential relative to nondisplaceable tissue (cerebellar grey matter) uptake (BPND) at baseline and after (-)-OSU6162 administration were generated using the simplified reference tissue model. MRI-based regions of interest were defined for the striatum, composed of caudate nucleus and putamen, and projected onto the co-registered parametric [(11)C]raclopride BPND image. Furthermore, three striatal subregions, ie, anterior dorsal caudate, anterior dorsal putamen, and ventral striatum, were defined manually and additionally analyzed. Plasma concentrations of (-)-OSU6162, ranging from 0.01 to 0.9 μM, showed a linear relationship with prolactin levels, reflecting blockade of pituitary D2 receptors. A concentration-dependent increase in striatal D2/D3 receptor occupancy was observed, reaching a value of about 20% at an (-)-OSU6162 plasma level of 0.2 μM, and which for higher concentrations leveled off to a maximal occupancy of about 40%. Findings were similar in the striatal subregions. The present data corroborate the notion that (-)-OSU6162 binds preferentially to a subpopulation of D2/D3 receptors, possibly predominantly extrasynaptic, and this may form the basis for the dopamine-stabilizing properties of (-)-OSU6162.

show abstract

“…The osteosono-assessment index (OSI) was calculated as a function of SOS and TI, using the TI value multiplied by the square of the SOS value [19]. We assessed the precision of quantitative ultrasound densitometry, and intratest precision was calculated from 3 repeated scans with repositioning in 17 volunteers; the short-term coefficient of variation was 2.6% for the OSI measure [20]. Low bone mass was defined as a level equal to or less than -1.0 standard deviation below the mean OSI value of the reference group aged 20 to 39 years old.…”

Section: Methodsmentioning

confidence: 99%

Effect of age and disease on bone mass in Japanese patients with schizophrenia

et al. 2012

Self Cite

View full text Add to dashboard Cite

BackgroundThere have been a limited number of studies comparing bone mass between patients with schizophrenia and the general population. The aim of this study was to compare the bone mass of schizophrenia patients with that of healthy subjects in Japan.MethodsWe recruited patients (n = 362), aged 48.8 ± 15.4 (mean ± SD) years who were diagnosed with schizophrenia or schizoaffective disorder based on the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV). Bone mass was measured using quantitative ultrasound densitometry of the calcaneus. The osteosono-assessment index (OSI) was calculated as a function of the speed of sound and the transmission index. For comparative analysis, OSI data from 832 adults who participated in the Iwaki Health Promotion Project 2009 was used as representative of the general community.ResultsMean OSI values among male schizophrenic patients were lower than those in the general population in the case of individuals aged 40 and older. In females, mean OSI values among schizophrenic patients were lower than those in the general community in those aged 60 and older. In an analysis using the general linear model, a significant interaction was observed between subject groups and age in males.ConclusionsOlder schizophrenic patients exhibit lower bone mass than that observed in the general population. Our data also demonstrate gender and group differences among schizophrenic patients and controls with regard to changes in bone mass associated with aging. These results indicate that intervention programs designed to delay or prevent decreased bone mass in schizophrenic patients might be tailored according to gender.

show abstract

No association between bone mass and prolactin levels among patients with schizophrenia

Cited by 22 publications

References 36 publications

Prevalence and Factors Associated With Decreased Bone Mineral Density in Young and Middle-Aged Male Schizophrenic Patients

Prevalence and Factors Associated With Decreased Bone Mineral Density in Young and Middle-Aged Male Schizophrenic Patients

The Dopamine Stabilizer (−)-OSU6162 Occupies a Subpopulation of Striatal Dopamine D2/D3 Receptors: An [11C]Raclopride PET Study in Healthy Human Subjects

Effect of age and disease on bone mass in Japanese patients with schizophrenia

Contact Info

Product

Resources

About